Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Aimpart XL 2mg tablets
0409010H0BHAAAK
|
Aimpart XL | Ropinirole hydrochloride | Central Nervous System | No data available |
|
Aimpart XL 4mg tablets
0409010H0BHABAL
|
Aimpart XL | Ropinirole hydrochloride | Central Nervous System | No data available |
|
Aimpart XL 8mg tablets
0409010H0BHACAM
|
Aimpart XL | Ropinirole hydrochloride | Central Nervous System | No data available |
|
Ajovy 225mg/1.5ml solution for injection pre-filled pens
0407042R0BBABAB
|
Ajovy | Fremanezumab | Central Nervous System | No data available |
|
Ajovy 225mg/1.5ml solution for injection pre-filled syringes
0407042R0BBAAAA
|
Ajovy | Fremanezumab | Central Nervous System | No data available |
|
Akineton 2mg tablets
0409020G0BBAAAC
|
Akineton (Oral) | Biperiden hydrochloride | Central Nervous System | No data available |
|
Akynzeo 300mg/0.5mg capsules
0406000AGBBAAAA
|
Akynzeo | Netupitant/palonosetron hydrochloride | Central Nervous System | No data available |
|
Alka Rapid Crystals 500mg granules sachets
0407010B0BRAACB
|
Alka Rapid | Aspirin | Central Nervous System | No data available |
|
Alka-Seltzer effervescent tablets original
0407010W0BGABA0
|
Alka-Seltzer | Aspirin combined preparations | Central Nervous System | No data available |
|
Allegron 10mg tablets
0403010V0BBAAAD
|
Allegron | Nortriptyline | Central Nervous System | No data available |
|
Allegron 25mg tablets
0403010V0BBABAE
|
Allegron | Nortriptyline | Central Nervous System | No data available |
|
Alli 27mg chewable tablets
0405010P0BCABAC
|
Alli | Orlistat | Central Nervous System | No data available |
|
Aloxi 250micrograms/5ml solution for injection vials
0406000ABBBAAAA
|
Aloxi | Palonosetron hydrochloride | Central Nervous System | No data available |
|
Aloxi 500microgram capsules
0406000ABBBABAB
|
Aloxi | Palonosetron hydrochloride | Central Nervous System | No data available |
|
Alzhok 10mg soluble tablets
0411000G0BGAAAH
|
Alzhok | Memantine hydrochloride | Central Nervous System | No data available |
|
Alzhok soluble tablets treatment initiation pack
0411000G0BGACA0
|
Alzhok | Memantine hydrochloride | Central Nervous System | No data available |
|
Amfetamine 10mg / Dexamfetamine 10mg modified-release caps
0404000L0AAAFAF
|
Dexamfetamine sulfate | Dexamfetamine sulfate | Central Nervous System | No data available |
|
Amfetamine 12.5mg / Dexamfetamine 12.5mg MR caps
0404000L0AABFBF
|
Dexamfetamine sulfate | Dexamfetamine sulfate | Central Nervous System | No data available |
|
Amfetamine 2.5mg / Dexamfetamine 2.5mg modified-release caps
0404000L0AABDBD
|
Dexamfetamine sulfate | Dexamfetamine sulfate | Central Nervous System | No data available |
|
Amfetamine 5mg / Dexamfetamine 5mg modified-release capsules
0404000L0AABHBH
|
Dexamfetamine sulfate | Dexamfetamine sulfate | Central Nervous System | No data available |
|
Amfetamine 5mg / Dexamfetamine 5mg tablets
0404000L0AAAVAV
|
Dexamfetamine sulfate | Dexamfetamine sulfate | Central Nervous System | No data available |
|
Amfetamine 7.5mg / Dexamfetamine 7.5mg modified-release caps
0404000L0AABEBE
|
Dexamfetamine sulfate | Dexamfetamine sulfate | Central Nervous System | No data available |
|
Amisulpride 12.5mg/5ml oral liquid
0402010A0AAAJAJ
|
Amisulpride | Amisulpride | Central Nervous System | No data available |
|
Amisulpride 200mg/5ml oral solution
0402010A0AAAMAM
|
Amisulpride | Amisulpride | Central Nervous System | No data available |
|
Amisulpride 50mg/5ml oral liquid
0402010A0AAACAC
|
Amisulpride | Amisulpride | Central Nervous System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.